Furthermore, the ATO/ATRA drug combination which targets PML-NBs in acute promyelocytic leukemias has been shown to be effective in IDH-mutated AML [68], suggesting a possible PML involvement. The gene discussed is IDH2; the disease is acute promyelocytic leukemia.